<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02190721</url>
  </required_header>
  <id_info>
    <org_study_id>XM02-ONC-201</org_study_id>
    <secondary_id>2014-001772-55</secondary_id>
    <nct_id>NCT02190721</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement</brief_title>
  <official_title>A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 ?g/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and
      efficacy of daily subcutaneous administration of 5 μg/kg tbo-filgrastim in infants, children
      and adolescents with solid tumors without bone marrow involvement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2015</start_date>
  <completion_date type="Actual">April 4, 2017</completion_date>
  <primary_completion_date type="Actual">April 4, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with Adverse Events</measure>
    <time_frame>90 Days</time_frame>
    <description>Safety will be assessed by evaluating adverse event reports throughout the study using descriptive statistics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in blood lab results</measure>
    <time_frame>Day 1 and 21</time_frame>
    <description>clinical laboratory test results at screening and at the end-of-study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Vital Signs</measure>
    <time_frame>21 Days</time_frame>
    <description>vital sign measurements at screening, throughout the study treatment, and at the end-of-study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiography (ECG) findings</measure>
    <time_frame>Day 1, 4 &amp; 6 hours post dose, Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medication usage</measure>
    <time_frame>90 Days</time_frame>
    <description>Any concomitant medication usage throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spleen sonography</measure>
    <time_frame>Day 1, 4, and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tolerability at the injection site</measure>
    <time_frame>1 hour (±30 minutes) after each study drug injection</time_frame>
    <description>Using Local Tolerability Assessment Scale ranging from Pain severity 0 (Absent) to 3 (Spontaneously painful)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody assessment</measure>
    <time_frame>Day 1, 21, and 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>90 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma/serum drug concentration (Cmax)</measure>
    <time_frame>12 Hours</time_frame>
    <description>Up to 12 Hours from Filgrastim administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed drug concentration (tmax)</measure>
    <time_frame>12 Hours</time_frame>
    <description>Up to 12 Hours from Filgrastim administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the serum drug concentration (AUC0-12)</measure>
    <time_frame>12 hours</time_frame>
    <description>area under the serum drug concentration by time curve from time 0 to 12 hours postdose (AUC0-12) Up to 12 Hours from Filgrastim administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration (AUC0-∞)</measure>
    <time_frame>12 Hours</time_frame>
    <description>Up to 12 Hours from Filgrastim administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t½)</measure>
    <time_frame>12 Hours</time_frame>
    <description>Up to 12 Hours from Filgrastim administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe neutropenia (DSN, ANC &lt;0.5 × 109/L)</measure>
    <time_frame>Day 15</time_frame>
    <description>During Cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of absolute neutrophil count (AUCANC)</measure>
    <time_frame>Day 15</time_frame>
    <description>During Cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANC nadir (measured in 109/L)</measure>
    <time_frame>Day 15</time_frame>
    <description>During Cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ANC nadir</measure>
    <time_frame>Day 15</time_frame>
    <description>During Cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ANC recovery to ≥1.0 × 109/L</measure>
    <time_frame>Day 15</time_frame>
    <description>During Cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ANC recovery to ≥2.0 × 109/</measure>
    <time_frame>Day 15</time_frame>
    <description>During Cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia</measure>
    <time_frame>15 Days</time_frame>
    <description>During cycle 1: The first dose of tbo-filgrastim will be administered after 24 hours (±3 hours) following the end of myelosuppressive chemotherapy (CTX) in week 1 of the study cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of severe neutropenia (DSN, ANC &lt;0.5 × 109/L)</measure>
    <time_frame>Day 15</time_frame>
    <description>During Cycle 1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>tbo-filgrastim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive subcutaneous doses of tbo-filgrastim 5 μg/kg body weight daily; each daily dose, to be administered at the investigative site</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tbo-filgrastim</intervention_name>
    <description>5 μg/kg</description>
    <arm_group_label>tbo-filgrastim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. Male or female infants, children and adolescents aged 1 month to &lt;16 years.

          2. Patients with solid tumors without bone marrow involvement, who are scheduled to
             receive myelosuppressive CTX.

          3. Body weight ≥5 kg.

          4. Patients must have an initial diagnosis and histologic proof of their malignancy. All
             enrolled subjects should have signed consent for a CTX regimen that is known to be
             myelotoxic, with counts expected to drop below the absolute neutrophil count (ANC) of
             0.5 × 109/L for at least 3 days. These regimens would include at least one of the
             following:

               -  Etoposide

               -  doxorubicin

               -  ifosfamide

               -  cyclophosphamide

          5. ANC and platelet count: Patients must have an ANC &gt;1 × 109/L and a platelet count &gt;100
             × 109/L to be eligible for therapy at the start of CTX.

          6. Normal cardiac, renal, and hepatic function.

          7. All subjects must have a life expectancy of 12 weeks or more.

          8. Performance Status: Lansky performance score &gt;60 (age 1 to &lt;16 years).

               -  More criteria may apply, please contact the investigator for more information.

        Exclusion:

          1. Bone marrow involvement.

          2. Active myelogenous leukemia or history of myelogenous leukemia.

          3. Previous treatment with colony-stimulating factors (granulocyte colony-stimulating
             factor [G-CSF], granulocyte-macrophage colony-stimulating factor, interleukin 11
             [IL-11]) less than 6 weeks prior to study entry.

          4. History of congenital neutropenia or cyclic neutropenia.

          5. Pregnant or nursing female patients.

          6. Fertile patients who do not agree to use highly reliable contraceptive measures Prior
             bone marrow or stem cell transplant, or prior radiation to ≥25% of bone marrow within
             the 4 weeks prior to the first tbo-filgrastim dose.

          7. Ongoing active infection or history of infectious disease within 2 weeks prior to the
             screening visit.

          8. Treatment with lithium at screening or planned during the study

               -  More criteria may apply, please contact the investigator for more information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 12958</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 12951</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 12954</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 12953</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 12959</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 12960</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 12957</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 59104</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 59105</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 60015</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 60014</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 60016</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 51186</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 51185</name>
      <address>
        <city>Budapest</city>
        <zip>1094</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 51184</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53249</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53248</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53245</name>
      <address>
        <city>Warszawa</city>
        <zip>01-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53246</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53247</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 52063</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 52064</name>
      <address>
        <city>Cluj-Napoca, Cluj</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 52065</name>
      <address>
        <city>Timisoara</city>
        <zip>300383</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50282</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50281</name>
      <address>
        <city>Krasnodar</city>
        <zip>350007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50284</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50280</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50283</name>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 58147</name>
      <address>
        <city>Kharkiv</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 58145</name>
      <address>
        <city>Kyiv</city>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 58148</name>
      <address>
        <city>Lviv</city>
        <zip>79035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 58146</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 58149</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Serbia</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2014</study_first_submitted>
  <study_first_submitted_qc>July 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2014</study_first_posted>
  <disposition_first_submitted>April 6, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 9, 2018</disposition_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 18, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

